新辅助化疗对骨肉瘤组织中β-catenin蛋白表达的影响  

Effect of neoadjuvant chemotherapy on expression of Beta-catenin protein in osteosarcoma

作　　者：杨建柱[1] 孙丽霞 丁洋[1] 刘俊茹[1] 王冬[1] 高峰[1] 

机构地区：[1]河北医科大学第三医院病理科,石家庄市050051 [2]河北医科大学第三医院血液科,石家庄市050051

出　　处：《河北医药》2010年第13期1679-1681,共3页Hebei Medical Journal

基　　金：河北省科学技术研究与发展支撑计划项目(编号:072761719)

摘　　要：目的探讨β-catenin蛋白在新辅助化疗前、后骨肉瘤组织中的表达变化及其与骨肉瘤临床病理特征的关系。方法通过免疫组织化学方法检测54例新辅助化疗前、后骨肉瘤组织,骨样骨瘤11例,骨母细胞瘤7例及反应性新生骨8例组织中β-catenin蛋白的表达,并结合临床资料进行相关分析。结果β-catenin蛋白在大部分骨样骨瘤、骨母细胞瘤及反应性新生骨病例中胞膜正常表达,而在骨肉瘤病例中胞浆(核)异常表达。新辅助化疗前骨肉瘤组织中β-catenin蛋白的异常表达率明显高于骨样骨瘤、骨母细胞瘤及反应性新生骨组织,差异具有统计学意义(P<0.01)。新辅助化疗前β-catenin蛋白异常表达率在骨肉瘤肺转移组明显高于无肺转移组(P<0.05)。新辅助化疗后骨肉瘤β-catenin蛋白异常表达较化疗前降低或消失(P<0.01),其表达与肿瘤坏死率不存在相关性。结论β-catenin蛋白可能成为良、恶性成骨肿瘤鉴别诊断有益的辅助指标。新辅助化疗前β-catenin蛋白高异常表达率与骨肉瘤患者肺转移关系密切。新辅助化疗可降低骨肉瘤组织中β-catenin蛋白的异常表达,可在一定程度上反映新辅助化疗的疗效。Objective To investigate the expression of beta-catenin in osteosarcoma before and after the neoadjuvant chemotherapy and to explore the relationship between the positive rate of beta-catenin and clinical pathological features. Methods The expressions of beta-catenin protein were detected by immunohistochemical stain in 54 cases of osteosarcoma before and after neoadjuvant chemotherapy, including 11 cases of osteoidosteoma, 7 cases of osteoblastoma and 8 cases of newly formed bone in non - malignant bone disease. Results The membrane localization of beta-catenin was found in osteoidosteoma, osteoblastoma and newly formed bone in non - malignant bone disease group, while translocation of beta-catenin to the cytoplasm and/or nucleus of osteosarcoma cells was detected in osteosarcoma group. The aberrant expression rate of beta-catenin protein in osteosarcoma group was significantly higher than that in osteoidosteoma, osteoblastoma and newly formed bone in nonmalignant bone diseases group （ P 〈 0. 01 ）. The aberrant expression rate of beta-catenin protein in osteosarcoma group with pulmonary metastasis was significantly higher than that in non-pulmonary metastasis group （ P 〈 0.05 ）. The aberrant expression of beta-catenin protein in osteosarcoma group became lower or disappeared after neoadjuvant chemotherapy（ P 〈 0.01 ）. But the expression of beta-catenin had no relationship with tumor cell necrosis rate （TCNR）. Conclusion The aberrant expression rate of beta-catenin in osteosarcoma is significantly higher than that in non - malignant bone tumors. The detection of beta-catenin protein may be a helpful marker in identification of benign and malignant bone tumors. The aberrant expression of beta-catenin protein has close relationship with pulmonary metastasis in osteosarcoma. The aberrant expression of beta-catenin protein in osteosarcoma decreases or disappeares after neoadjuvant chemotherapy, to some degree, which may evaluate the efficiency of neoadjuvant chemotherapy.

关 键 词：骨肉瘤 肺转移 Β-CATENIN蛋白 免疫组织化学 新辅助化疗 

分 类 号：R738.1[医药卫生—肿瘤]